Abstract
The optimization of DOTA-NHS-ester conjugation to Rituximab using different Ab:DOTA molar ratios (1:10, 1:20, 1:50 and 1:100) was studied. High radiochemical yield, in vitro stability and immunoreactive fraction were obtained for the Rituximab conjugated at 1:50 molar ratio, resulting in the incorporation of an average number of 4.9 ± 1.1 DOTA per Rituximab molecule. Labeling with 177Lu was performed in high specific activity with great in vitro stability. Biodistribution in healthy and xenographed mice showed tumor uptake and high in vivo stability as evidenced by low uptake in bone. The properties of 177Lu-DOTA-Rituximab prepared from DOTA-NHS-ester suggest the potential for the application of the 177Lu-labeled antibody in preliminary clinical studies.
Keywords: Anti-CD-20, DOTA-NHS-ester, immunoconjugation, Non-Hodgking‘s Limphoma, radioimmunotherapy, Rituximab.
Current Radiopharmaceuticals
Title:Development and biological studies of 177Lu-DOTA-rituximab for the treatment of Non-Hodgkin’s lymphoma
Volume: 9 Issue: 1
Author(s): Adriana V.F. Massicano, Priscilla B. Pujatti, Lais F. Alcarde, Miriam F. Suzuki, Patrick J. Spencer and Elaine B. Araújo
Affiliation:
Keywords: Anti-CD-20, DOTA-NHS-ester, immunoconjugation, Non-Hodgking‘s Limphoma, radioimmunotherapy, Rituximab.
Abstract: The optimization of DOTA-NHS-ester conjugation to Rituximab using different Ab:DOTA molar ratios (1:10, 1:20, 1:50 and 1:100) was studied. High radiochemical yield, in vitro stability and immunoreactive fraction were obtained for the Rituximab conjugated at 1:50 molar ratio, resulting in the incorporation of an average number of 4.9 ± 1.1 DOTA per Rituximab molecule. Labeling with 177Lu was performed in high specific activity with great in vitro stability. Biodistribution in healthy and xenographed mice showed tumor uptake and high in vivo stability as evidenced by low uptake in bone. The properties of 177Lu-DOTA-Rituximab prepared from DOTA-NHS-ester suggest the potential for the application of the 177Lu-labeled antibody in preliminary clinical studies.
Export Options
About this article
Cite this article as:
Massicano V.F. Adriana, Pujatti B. Priscilla, Alcarde F. Lais, Suzuki F. Miriam, Spencer J. Patrick and Araújo B. Elaine, Development and biological studies of 177Lu-DOTA-rituximab for the treatment of Non-Hodgkin’s lymphoma, Current Radiopharmaceuticals 2016; 9 (1) . https://dx.doi.org/10.2174/1874471008666150313103849
DOI https://dx.doi.org/10.2174/1874471008666150313103849 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
B Cells: Programmers of CD4 T Cell Responses
Infectious Disorders - Drug Targets Biologics in Polymyositis and Dermatomyositis-Associated Interstitial Lung Disease
Current Pharmaceutical Biotechnology Randomised Trials of Graft Versus Host Disease Prophylaxis in Haemopoietic Stem Cell Transplantation
Reviews on Recent Clinical Trials Genetically Redirected T Lymphocytes for Adoptive Immunotherapy of Solid Tumors
Current Gene Therapy Targeting the Voltage-Dependent K+ Channels Kv1.3 and Kv1.5 as Tumor Biomarkers for Cancer Detection and Prevention
Current Medicinal Chemistry 86Y Based PET Radiopharmaceuticals: Radiochemistry and Biological Applications
Medicinal Chemistry Actinium-225 in Targeted Alpha-Particle Therapeutic Applications
Current Radiopharmaceuticals Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets Gene Silencing in the Development of Personalized Cancer Treatment: The Targets, the Agents and the Delivery Systems
Current Gene Therapy Formulation and Evaluation of Rifampicin Liposomes for Buccal Drug Delivery
Current Drug Delivery Derivatives of Procaspase-Activating Compound 1 (PAC-1) and their Anticancer Activities
Current Medicinal Chemistry Third Generation Radiopharmaceuticals for Imaging and Targeted Therapy
Current Pharmaceutical Analysis HDL Genetic Defects
Current Pharmaceutical Design Paclitaxel Formulations: Challenges and Novel Delivery Options
Current Drug Delivery The Formulation of Lipid-Based Nanotechnologies for the Delivery of Fixed Dose Anticancer Drug Combinations
Current Drug Delivery Monoclonal Antobodies: Application in Radiopharmacy
Current Radiopharmaceuticals Protein Phosphatase 1 and Its Complexes in Carcinogenesis
Current Cancer Drug Targets Sodium Selenite Decreased HDAC Activity, Cell Proliferation and Induced Apoptosis in Three Human Glioblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry Recent Clinical Trials of Cladribine in Hematological Malignancies and Autoimmune Disorders
Reviews on Recent Clinical Trials Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs
Current Cancer Drug Targets